Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB lessened its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 3.3% in the 4th quarter, Holdings Channel reports. The fund owned 290,000 shares of the company’s stock after selling 10,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Nurix Therapeutics were worth $5,464,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in NRIX. US Bancorp DE raised its holdings in Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after purchasing an additional 842 shares in the last quarter. Quarry LP increased its position in Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after purchasing an additional 2,435 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Nurix Therapeutics during the 4th quarter worth approximately $209,000. EP Wealth Advisors LLC purchased a new position in shares of Nurix Therapeutics during the 3rd quarter worth approximately $240,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Nurix Therapeutics in the 4th quarter valued at approximately $266,000.

Insider Buying and Selling

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now owns 55,937 shares of the company’s stock, valued at $1,110,349.45. This represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Houte Hans Van sold 5,825 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the sale, the chief financial officer now owns 33,724 shares in the company, valued at $488,660.76. This trade represents a 14.73 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,326 shares of company stock worth $213,449. 7.20% of the stock is owned by insiders.

Nurix Therapeutics Stock Down 7.8 %

NRIX opened at $9.69 on Friday. The business’s fifty day simple moving average is $15.45 and its 200 day simple moving average is $19.93. Nurix Therapeutics, Inc. has a 52 week low of $9.45 and a 52 week high of $29.56. The firm has a market cap of $738.73 million, a P/E ratio of -3.35 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. As a group, equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on NRIX shares. Leerink Partners began coverage on Nurix Therapeutics in a report on Monday, March 17th. They set a “market perform” rating and a $16.00 price objective on the stock. Needham & Company LLC lowered their price target on shares of Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Morgan Stanley raised their price objective on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, February 3rd. Stephens restated an “overweight” rating and set a $31.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Finally, JPMorgan Chase & Co. dropped their target price on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, Nurix Therapeutics has an average rating of “Moderate Buy” and an average price target of $30.88.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.